- Price
- $141.68
- Day
- +1.30%
- Mkt Cap
- $16.36B
- 52W Range
- $108.50 – $217.64
- Volume
- 1.39M
- Beta
- 0.99
Find a company by name or ticker and open its page
Breaking news, press releases, and analyst updates.
Most recent articles and analysis covering this company.
PTC's tighter focus on product data, lifecycle software and AI sharpens its growth story, but fourth-quarter ARR conversion remains the key execution test.
Read full article
PTC is turning governed product data, cloud collaboration and focused AI pilots into broader industrial software and service opportunities.
Read full article
PTC's valuation reset and buybacks improve its risk-reward profile, but weak revenue, margin pressure and a demanding fourth quarter keep execution in focus.
Read full article
Arrowstreet Capital Limited Partnership reduced its position in PTC Inc. (NASDAQ: PTC) by 28.7% during the undefined quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 105,797 shares of the technology company's stock after selling 42,605 shares during the period. Arrowstreet Capital Limited Partnership
Read full article
Amundi increased its holdings in shares of PTC Inc. (NASDAQ: PTC) by 151.9% during the undefined quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 1,725,555 shares of the technology company's stock after buying an additional 1,040,656 shares during the period. Amundi
Read full article
PTC lifted its fiscal 2026 revenue, EPS and ARR outlook, despite quarterly revenue and earnings missing expectations.
Read full article
Constant Currency ARR (excluding Kepware and ThingWorx): $2.448 billion, up 9.1% year-over-year.Net New ARR: $60 million in Q3.Revenue: $600 million in Q3.Opera
Read full article
– Robust Q2 performance with total revenue of $361 million, including $239 million of product revenue – – Full-year 2026 expected total revenue increased to $1.18 to $1.28 billion, with full-year product revenue guidance raised to $850 to $950 million – – Sephience™ (sepiapterin) Q2 2026 revenue of $151 million, with continued broad uptake and geographical expansion – – Strong cash position of $2.2 billion as of June 30, 2026 – WARREN, N.J., July 30, 2026 /PRNewswire/ -- PTC Therapeutics, Inc., (NASDAQ: PTCT) today announced a corporate update and financial results for the second quarter ended June 30, 2026.
Read full article
PTC Inc. (PTC) Q3 2026 Earnings Call Transcript
Read full article
Although the revenue and EPS for PTC Inc. (PTC) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Read full article
PTC Inc. (PTC) came out with quarterly earnings of $1.58 per share, missing the Zacks Consensus Estimate of $1.6 per share. This compares to earnings of $1.64 per share a year ago.
Read full article
Strategic focus on Intelligent Product Lifecycle vision Strong execution in Q3'26 across all key metrics Constant currency ARR growth of 9.1% excluding divested businesses, exceeding the high end of our guidance range Operating and free cash flow growth of 7% and 3%, respectively, both exceeding the high end of our guidance ranges Raising FY'26 guidance for ARR, Revenue and EPS, reaffirming Cash Flow guidance ~$525 million of shares repurchased in Q3'26, bringing FY'26 repurchases above the high-end of our target for the year BOSTON, July 29, 2026 /PRNewswire/ -- PTC (NASDAQ: PTC) today reported financial results for its third fiscal quarter ended June 30, 2026. "PTC delivered strong financial execution in Q3'26.
Read full article